HOME >> BIOLOGY >> NEWS
Vax and Pax: Taking turns to build an eye

Opposing ball clubs don't take the field at the same time, and neither do teams of proteins responsible for creating the eye. While one team builds the retina, in adjacent cellular turf the opponents are busy constructing the cord that carries visual signals to the brain. And these guys aren't supposed to mingle.

That's why researchers at the Salk Institute for Biological Studies were surprised to find the respective team captains--Vax2, a protein that along with Vax1 builds the optic nerve cord, and Pax6, a protein that drives retinal fate--playing on the same field. That puzzle is explained in a forthcoming paper in Genes and Development.

Earlier studies from the laboratory of Greg Lemke, Ph.D., professor in Salk's Molecular Neurobiology Laboratory, had shown that Vax2 antagonized Pax6. "We knew that Vax1 and 2 acted together to inactivate Pax6. That's how you get an optic nerve--by preventing it from becoming a retina," explains Lemke. The only problem was that later on both Vax2 and Pax6 were co-expressed in the same cells. "If Vax2 was repressing Pax6 this seemed inconsistent," he says.

Both proteins bind DNA and function in a cell's nucleus to switch genes on and off. Pax6 regulates the development of the retina, while Vax2 ensures that the optic nerve gets built. Finding both proteins in the same nucleus would make about as much sense as having runners for the Giants and the Dodgers on base at the same time.

Analyzing eye development in both mouse and chick tissues, Lemke and former postdoctoral fellow Jin Woo Kim, Ph.D., solved the mystery. Stina Mui, a former graduate student in the Lemke lab had originally observed Vax2 in the cytoplasm of cultured cell lines and Kim had taken on the task of figuring out why. He showed that Vax2 protein is indeed expressed in the same retinal cells as Pax6, but that Vax2 shuttles in and out of the nucleus in response to a signaling molecule known as Sonic hedgehog.

"Va
'"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
858-453-4100 x1340
Salk Institute
14-Oct-2006


Page: 1 2 3

Related biology news :

1. Taking a supplement of glycine helps prevent degenerative diseases such as arthrosis or osteoporosis
2. Taking heart failure to the MAT1
3. Taking chips to the next level of gene hunting
4. Taking evolutions temperature: Researchers pinpoint the energy it takes to make a species
5. Taking a bite out of a fellow worker helps wasps recruit new foragers
6. Taking a break from fractures: A closer look at vitamin D
7. Taking a flying jump
8. Taking the piste out of Alpine vegetation
9. Taking the next step toward growing our own fuel
10. OHSU turns mouse into factory for human liver cells
11. Leukemia drug turns mini-molecules up, cancer genes down

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
Cached News: